We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Eli Lilly, Mitsubishi UFJ, Thermo Fisher, Oracle and Ecolab
Read MoreHide Full Article
For Immediate Release
Chicago, IL –December 20, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly and Company (LLY - Free Report) , Mitsubishi UFJ Financial Group, Inc. (MUFG - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) , Oracle (ORCL - Free Report) and Ecolab (ECL - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for Lilly, Mitsubishi UFJ and Thermo Fisher
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company, Mitsubishi UFJ Financial Group, Inc. and Thermo Fisher Scientific Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Buy-ranked Eli Lilly’s shares have gained +26.1% year to date, significantly outperforming the Zacks Large Cap Pharmaceuticals industry, which has gained +2.4% over the same period. Lilly’s new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance, Lartruvo and Verzenio are expected to drive revenues.
The company expects to launch 20 new products by 2023, including at least two new indications/line extensions on average every year. Lilly is also having a strong year in terms of its pipeline with several positive late-stage data readouts and regulatory nods.
The newly launched CGRP antibody, Emgality could emerge as a significant contributor to long-term growth. It has also added promising new assets through business development deals. The stock has also outperformed the industry this year so far.
Shares of Mitsubishi UFJ Financial have declined 12% in the last six months, underperforming the Zacks Foreign Banks industry which has declined 9.6% over the same period. Strong capital ratios and organic growth are likely to drive the company’s bottom-line growth. Also, the company’s prospects look encouraging, as it focuses on several strategies under its medium-term business plan and global expansion.
Nonetheless, the company's revenues continue to remain under pressure due to the negative interest rates in Japan. Also, rising costs due to strict regulations in overseas business remains a key concern.
Shares of Buy-ranked Thermo Fisher have outperformed the Zacks Medical Instruments industry in the past three months (-5% vs. -15.1%). The company saw strength in all end markets categorized by customer type or geography in the last reported quarter. It particularly registered solid international performance with strong growth in Asia-Pacific including China. Also, a series of product launches with progress in precision medicine initiatives aided its performance.
The company’s recently-closed acquisition of Advanced Bioprocessing business from BD should add complementary cell culture products to Thermo Fisher’s bioproduction offerings. Also, the company’s initiative to buy Gatan to boost electron microscopy suite buoys optimism.
Other noteworthy reports we are featuring today include Oracle and Ecolab.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Eli Lilly, Mitsubishi UFJ, Thermo Fisher, Oracle and Ecolab
For Immediate Release
Chicago, IL –December 20, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly and Company (LLY - Free Report) , Mitsubishi UFJ Financial Group, Inc. (MUFG - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) , Oracle (ORCL - Free Report) and Ecolab (ECL - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for Lilly, Mitsubishi UFJ and Thermo Fisher
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company, Mitsubishi UFJ Financial Group, Inc. and Thermo Fisher Scientific Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Buy-ranked Eli Lilly’s shares have gained +26.1% year to date, significantly outperforming the Zacks Large Cap Pharmaceuticals industry, which has gained +2.4% over the same period. Lilly’s new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance, Lartruvo and Verzenio are expected to drive revenues.
The company expects to launch 20 new products by 2023, including at least two new indications/line extensions on average every year. Lilly is also having a strong year in terms of its pipeline with several positive late-stage data readouts and regulatory nods.
The newly launched CGRP antibody, Emgality could emerge as a significant contributor to long-term growth. It has also added promising new assets through business development deals. The stock has also outperformed the industry this year so far.
(You can read the full research report on Eli Lilly here >>>).
Shares of Mitsubishi UFJ Financial have declined 12% in the last six months, underperforming the Zacks Foreign Banks industry which has declined 9.6% over the same period. Strong capital ratios and organic growth are likely to drive the company’s bottom-line growth. Also, the company’s prospects look encouraging, as it focuses on several strategies under its medium-term business plan and global expansion.
Nonetheless, the company's revenues continue to remain under pressure due to the negative interest rates in Japan. Also, rising costs due to strict regulations in overseas business remains a key concern.
(You can read the full research report on Mitsubishi UFJ here >>>).
Shares of Buy-ranked Thermo Fisher have outperformed the Zacks Medical Instruments industry in the past three months (-5% vs. -15.1%). The company saw strength in all end markets categorized by customer type or geography in the last reported quarter. It particularly registered solid international performance with strong growth in Asia-Pacific including China. Also, a series of product launches with progress in precision medicine initiatives aided its performance.
The company’s recently-closed acquisition of Advanced Bioprocessing business from BD should add complementary cell culture products to Thermo Fisher’s bioproduction offerings. Also, the company’s initiative to buy Gatan to boost electron microscopy suite buoys optimism.
(You can read the full research report on Thermo Fisher here >>>).
Other noteworthy reports we are featuring today include Oracle and Ecolab.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.